Amedica Announces Adjournment of Special Meeting of Stockholders
October 03 2017 - 10:25AM
Amedica Corporation (Nasdaq:AMDA), an innovative medical
device company that develops and commercializes silicon nitride,
announced that the special meeting of stockholders scheduled for
today has been adjourned.
The adjournment is to allow for the solicitation
of additional votes in favor of the proposal contained in the
definitive proxy statement that Amedica filed with the Securities
and Exchange Commission on July 28, 2017 regarding a reverse split
of the company's common stock. Approval of a majority of all
outstanding shares of Amedica common stock is necessary for this
proposal to be approved.
The special meeting will reconvene at 9:00 a.m.
local time on October 10, 2017 at the company’s offices located at
1885 West 2100 South, Salt Lake City, UT 84119. The record
date for stockholders entitled to vote at the special meeting
remains July 19, 2017.
During the period of the adjournment, Amedica
will continue to solicit proxies from its stockholders.
Stockholders who have not already done so are encouraged to vote -
because passage of the proposal requires a majority of outstanding
shares to vote in favor, unvoted shares have the same effect as
shares voted against. Stockholders who have already voted do
not need to recast their votes unless they wish to change their
votes. Proxies previously submitted for the meeting will be
voted as previously instructed at the reconvened meeting unless
properly revoked.
Both leading independent proxy advisory firms -
Institutional Shareholder Services Inc. and Glass Lewis & Co.
LLC - have recommended that stockholders vote in favor of the
reverse split proposal.
Today's adjournment provides stockholders who
have not yet voted an additional opportunity to do so. All
stockholders are reminded that every vote will count. Stockholders
who need assistance in voting their shares or who have questions
are encouraged to contact Amedica's proxy solicitor, Innisfree
M&A Incorporated, stockholders call toll-free at (888) 750-5834
and banks and brokers may call collect at (212) 750-5833.
About Amedica
CorporationAmedica is the only manufacturer of medical
grade silicon nitride - an innovative biomaterial technology ideal
for use in spinal fusion and across a variety of medical
applications. The Company’s products are manufactured in its ISO
13485 certified manufacturing facility located in Salt Lake City,
Utah. Amedica's FDA-cleared and CE-marked spine products are
currently marketed in the U.S. and select markets in Europe and
South America through its distributor network.
For more information on Amedica
or its silicon nitride material platform, please
visit www.amedica.com.
Forward-Looking Statements This
press release contains statements that constitute forward-looking
statements within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those contemplated within this press
release. A description of those risks can be found in
Amedica's Risk Factors disclosure in its Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC) on
September 20, 2017, and in Amedica's other filings with the SEC.
Amedica disclaims any obligation to update any forward-looking
statements.
Contacts:
Amedica IR
801-839-3502
IR@amedica.com
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024